Rapid point of care diagnosis of urinary tract infection

REVOLUTIONISING

the diagnosis and treatment of urinary tract infection (UTI)

REVOLUTIONISING

the diagnosis and treatment of urinary tract infection (UTI)

Innovative PhenUtest point-of-care test

Results in under an hour including full antimicrobial susceptibility test.

Ground-breaking technology with the potential to transform the diagnosis and treatment of urinary tract infection, a common condition associated with billions of dollars of annual healthcare costs globally. In the US alone these costs are in the order of $44bn.

Innovative PhenUtest point-of-care test

Results in under an hour including a full antimicrobial susceptibility test

Ground-breaking technology with the potential to transform the diagnosis and treatment of urinary tract infection, a common condition associated with billions of dollars of annual healthcare costs globally. In the US alone these costs are in the order of $44bn.¹

Accurate Results

Proprietary technology provides accurate results in less than an hour
For use in primary care, the community and emergency care
Expected to reduce hospitalisation and slow the growth of antimicrobial resistance (AMR)

Accurate Results

Proprietary technology provides accurate results in less than an hour
For use in primary care, the community and emergency care
Expected to reduce hospitalisation and slow the growth of antimicrobial resistance (AMR)

More than

150M

UTI infections a year globally, of which >71% of patients are women^{2, 3}

More than

150M

UTI infections a year globally, of which >71% of patients are women^{2, 3}

Current methods are time-consuming and often inaccurate

Current gold standard test take 48+ hours to deliver full antimicrobial susceptibility test (AST) results

Current methods are time-consuming and often inaccurate

Current gold standard tests take 48+ hours to deliver full antimicrobial susceptibility test (AST) results⁴

Latest News

PhenUtest Presents at LSI Europe ’24

Bath, UK, 20^th September 2024

PhenUtest Longlisted for the Nature Spinoff Prize

Bath, UK, 10^th June 2024

PhenUtest Secures Place on Texas Medical Center Innovation Accelerator

Bath, UK, 31^st May 2024

1.

Zilberberg et al., outcomes of ER visits with complicated UTIs, 2022
2.

Flores-Mireles et al., UTI epidemiology, mechanisms and treatment, 2015
3.

Simmering et al., Hospitalisations for UTI and Associated Cost, 2017
4.

Xu et al., Review of Current and Developing UTI diagnostics, 2021

This test has not been approved or cleared by the U.S. Food and Drug Administration.
The performance characteristics of this test have not been established.

Innotive Diagnostics Ltd
Second Floor
Riverside South Building
Walcot Yard
Walcot Street
Bath BA1 5BG

info@phenutest.com

Innotive Diagnostics Ltd
Second Floor
Riverside South Building
Walcot Yard
Walcot Street
Bath BA1 5BG

info@phenutest.com

@import url('https://fonts.googleapis.com/css2?family=Poppins:wght@700&display=swap'); REVOLUTIONISING

@import url('https://fonts.googleapis.com/css2?family=Poppins:wght@700&display=swap'); REVOLUTIONISING

Innovative PhenUtest point-of-care test

Innovative PhenUtest point-of-care test

Accurate Results

Accurate Results

More than

150M

UTI infections a year globally, of which >71% of patients are women2, 3

More than

150M

UTI infections a year globally, of which >71% of patients are women2, 3

Current methods are time-consuming and often inaccurate

Current methods are time-consuming and often inaccurate

Latest News

PhenUtest Presents at LSI Europe ’24

PhenUtest Longlisted for the Nature Spinoff Prize

PhenUtest Secures Place on Texas Medical Center Innovation Accelerator

REVOLUTIONISING

REVOLUTIONISING

UTI infections a year globally, of which >71% of patients are women^{2, 3}

UTI infections a year globally, of which >71% of patients are women^{2, 3}